nhia logo

Quick Links
Search NHIA.org



Baczewski D. Operational Challenges of Rising Fuel Costs. 2008;14(5):22-6.

Baczewski D. Non-compliance is not an option—Strengthening USP <797> compliance through proper clean room maintenance. 2013;19(6):22-25.

Baker Kenneth R. Sterile compounding oversight: Legal challenges, practice considerations.200713(2);20-3.

Bickley S. USP compliance: A journey. 2006. 12(5):32-6.

Chamallas SN, Fishwick J, Riesenberg M. Special delivery: Keeping the product stable during shipping. 1997;4(3):30-2.

Choy GS, Egging P, White B. Stability data for ambulatory infusion pump reservoirs. 1998;4(11):18-23.

Counce J. Digging deep: Infusion pharmacies bear the cost of USP <797> compliance. 2006:12(1):15-9.

Douglass K, Kastango E, and Canto P. Sterile Compounding and USP <797> Compliance: Where Does the Alternate-Site Pharmacy Setting Stand? 2012; 18(2):21-28.

Douglass K, and Kastango E. and Cantor P. The 2011 United States Pharmacopeia Chapter <797> Compliance Study: Discussion of Findings and Strategies for Improvement in the Alternate-Site Setting. 2012; 18(3):38-44.

Fagerman K. 4-Chamber total parenteral nutrition system: A "needleless" total nutrient admixture. 1997;3(12):15-9.

Ferris R. Pharmacoeconomics: Principals of balance. 1998;4(11):39-42.

Filibeck D and Counce J. It’s not just about the stickers: Building a positive relationship with a certifier is key to maintaining a state of aseptic control in your cleanroom. 2014;20(6):25-32.

Johnson K, Volkman G. Identifying and calculating activity-based pharmacy costs in home infusion and ambulatory care 1998;4(6):15-21.

Kastango ES and Bradshaw B. Sterile product compounding: Developing quality-based standards for pharmacy practice. 2003;9(1):23-7.

Kastango ES. USP <797>: Making the case for increasing environmental controls in pharmaceutical compounding. 2005.11(4):S1-S12.

Kastango E. USP chapter <797>: The next phase. 2006. 12(4):25-9.

Kastango E and Kramer N. The Top 10 Things You Need to Know About USP <797>. 2009:15(3);43-8.

Kastango E. Maintaining a state of control in sterile compounding—The intersection of professional responsibility and patient safety. 2013;19(6):28-35.

Leone M. Compounding considerations: New alert on exposure to hazardous drugs in the workplace. 2004;10(5):33-36.

Lima HA. Using media fills to evaluate aseptic technique. 1994;1(3):29-33.

NHIA.  New national standards on pharmaceutical compounding. 2004;10(1):20-2.

Nowobilski-Vasilios A and Bing C. Beyond-use dating of compounded sterile preparations—Effectively mapping out the complexities for better decision making. 2013;19(6):37-45.

Nowobilski-Vasilios A. Our collective responsibility. 2013;19(6):20-21.

Nowobilski-Vasilios A. State of the union—Sterile compounding: Overview of state legislative changes related to sterile preparation. 2014;20(6):19-24.

Nowobilski-Vasilios A. Our personal responsibility in an environment of change. 2014;20(6):15-17.

Petroff B and Baczewski D. Blueprint for Patient Safety: How informed clean room design can promote sterility. INFUSION.2015;21(6):27-33.

Rollins CJ. Aluminum content in parenteral products: What clinicians should know about preventing toxicity. 2005:11(1):27-35.

Schloerb PR. Electronic parenteral and enteral nutrition. 2000;6(8):45-7.

Sullivan C. Sterile Compounding in the Future: How Newly Proposed USP Standards Could Affect Your Practice. INFUSION.2015;21(6):22-25.

Sullivan C. Maintaining a Controlled Environment: Cleaning and disinfecting in the clean room. INFUSION.2015;21(6):36-43.

Van Pool K. Compounding pharmacy legislation passes House, awaiting Senate vote. 2013;19(6):14-18.

Van Pool K. Parsing Oversight of Home Infusion Pharmacies Under the Drug Quality and Security Act. INFUSION.2015;21(6):13-14.

Wagner JT. Interpreting cleanroom certification reports: What providers should know to ensure compliance. 2014;20(6):34-41.